Dilafor AB is a women’s health company based in Stockholm, Sweden, developing tafoxiparin for obstetric indications, with particular reference to protracted labor and associated complications. Protracted labor represents a significant unmet clinical need and is the major cause of emergency Caesarean Sections as well as several other serious complications affecting both the mother and the newborn baby. The company was founded in 2003 by scientists from Karolinska Institutet,  Lund University, Uppsala University and experts with significant experience from the pharmaceutical industry.